Coxiella burnetii (Q-Fever) Phase 2 IgM ELISA
- Regulatory Status
- EU: CE
- Kit size
- 12 x 8
- Method
- ELISA
- Incubation time
- 1 x 1h, 1 x 30 min, 1 x 15 min
- Standard range
- cut-off index
- Specimen / Volumes
- 10 µL serum
- Substrate / isotope
- TMB 450 nm
The Rickettsia Coxiella burnetii, a worldwide distributed pathogen, is responsible for the disease known as Q fever. The small gram-negative, obligate intracellular bacterium reproduces in the digestive system of ticks (Dermacentor marginatus) and placental trophoblasts. As a result tick faeces and afterbirths of infected mammals (particularly sheep) are highly infectious. Occupational groups with direct contact to farm animals are at particular risk of infection. In this group, antibodies against Coxiella burnetii can be detected in 30 to 70 %. Infection usually results from inhalation of contaminated aerosols, especially during dry summer months. The incubation time is around two to four weeks. Clinical symptoms are developed in 30 to 50 %, the remaining individuals (50 to 70 %) reveal subclinical or non-specific symptoms. Influenza-like symptoms are often evident. In about 50 % of cases an atypical, interstitial pneumonia develops. Less frequently, the infection results in a hepatitis. In a few cases, the acute phase may be complicated by meningoencephalitis, myocarditis or pericarditis. If not treated the pathogen persists in 1 to 11 % of all cases in a variety of organs, which ends after months or years, in a chronic infection. Chronic courses often lead to an endocarditis (especially patients with heart valve disease) and/or granulomatous hepatitis. About 65 % of chronic Q-fever cases are lethal. Following a primary infection antibodies directed against the phase 2 antigen are produced during the acute phase of Q fever disease. IgM antibodies appear approximately after two weeks followed by IgG with in two months post infection. While IgM antibodies can be detected up to three months post infection, IgG is frequently detectable for up to five years. Only when an infection enters the chronic stage IgA and IgG directed against the C. burnetii phase 1 antigen appear. These antibodies are particularly significant when diagnosing Q fever endocarditis. Due to the fact, that IgM antibodies directed against phase 1 antigen are not present after a longer time period, there is no sense of IgM detection during a chronic course. Rheumatoid factors are significantly increased in the chronic phase. Due to the lack of characteristic clinical symptoms of acute and chronic Q fever infection, diagnosis is based primarily on serologic techniques. The use of ELISA test systems is recommended by the WHO due to its high sensitivity and specificity and the possibility to perform a differential analysis of the antibody response. Following diseases should be considered for differential diagnosis: Chlamydia infections, Mycoplasma pneumoniae-infections, Legionella pneumophila- and Legionella micdadeiinfections, Virus-pneumonias and Leptospirosis.
Distributed by Tecan, IBL International GmbH.
For concrete data please consult the Instruction for Use in the download box on the top right side.
Our comprehensive immunoassay portfolio includes a number of specialty diagnostic immunoassays for endocrinology, immunology and autoimmunity, as well as for diagnosis of multiple infectious diseases. We are pioneers and market leaders in saliva diagnostics, with over 40 years of experience supplying a broad portfolio of luminescence- and ELISA-based tests, including our highly acclaimed HMGB1 and MuSK-Ab ELISAs.
And as experts in laboratory automation, we can support our customers with the protocols for open ELISA platforms, such as the Freedom EVOlyzer or Thunderbolt®.
All products are only available for sale to laboratory professionals and may not be available in all countries. Availability and regulatory status may vary across regions depending on local country-specific registration. Please always read and follow the instructions for use.
All of our assays have been designed and manufactured to meet the highest global regulatory requirements and quality standards. Tecan is certified under ISO 9001:2015, ISO 13485:2016 and is audited by a notified body according to Medical Device Single Audit Program (MDSAP).

As part of the Tecan Group, we have a leading market position in diagnostics and research, with over 40 years of experience in the development, manufacture and supply of enzyme-, radiolabel- and luminescence-based immunoassays.
Our range of high-quality immunoassays is supported by a diverse portfolio of automated solutions, making us the perfect partner for you and your customers.
At Tecan, we are driven to improve people’s lives and health.